"If this trial provides convincing evidence of benefit in this high mortality population, it has the potential to become a pivotal trial for Hemopure's use as an adjunct to AML induction chemotherapy when transfusion with blood components is refused by the patient. By serving as an oxygen delivery bridge following chemotherapy-induced suppression of red blood cell count, use of Hemopure, as part of a bloodless treatment regimen, may potentially reduce mortality in these patients, who currently have no hope."

— Zafiris Zafirelis, Biopure president/CEO, concerning the embattled company's discussions with the FDA to initiate a clinical trial of Hemopure for patients suffering from Acute Myelogenous, or Leukemia, "Hemopure clinical trial could be final hope for struggling Biopure," pp. 1, 7.